MedTrace Logo

Impact of Comorbidities, Some Biomarkers, Micro RNA in Childhood Asthma Phenotypes

NCT07230912 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 82

Last updated 2025-11-17

No results posted yet for this study

Summary

* Assess response to treatment in children with bronchial asthma attending Assiut university children hospital.
* Role of comorbidities in controlling symptoms of bronchial asthma.
* Evaluate the role of the soluable interleukin 5 receptor, I C-telopeptide of type I collagen (ICTP), miR-223-3p and miR-191-5p in bronchial asthma.

Conditions

  • Bronchial Asthma

Interventions

DRUG

Short Acting Beta 2 Agonist

short acting drug

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Mohamed Mahrous El Tallawy, professor of pediatrics · Assiut university children hospital

  • Yasser Gamal Abdel-Rahman, Assistant Professor · Assiut university children hospital

  • Ahmed Zohri Yasin, Lecturer of Pediatrics · Assiut university children hospital

Eligibility

Min Age
6 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-30
Primary Completion
2026-12-30
Completion
2027-02-28
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07230912 on ClinicalTrials.gov